Education
About Us
Working with TipRanks
Follow Us
Humacyte (HUMA)
NASDAQ:HUMA
Earnings Data
Report Date
May 09, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.2Last Year’s EPS
-0.29Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 28, 2025
|% Change Since: -32.84%
|Next Earnings Date:May 09, 2025
Earnings Call Sentiment|Neutral
The call highlighted significant achievements such as the FDA approval and successful launch of Symvess, as well as progress in the ATEV program. However, financial challenges remain with no revenue reported for 2024 and increased net losses. The sentiment reflects a balanced view of optimism for future growth and ongoing financial hurdles.Company Guidance
During the Humacyte Fourth Quarter Results Conference Call, the company provided detailed guidance on its recent achievements and future plans, with a strong focus on the commercial launch and anticipated expansion of its product, Symvess. Having received FDA approval for Symvess for extremity vascular trauma, the company highlighted significant engagement with hospitals, with 34 initiating the Value Analysis Committee (VAC) approval process and three already completing it. The company is optimistic about its NTAP application with CMS, which could commence reimbursement by October 1, 2025. Humacyte also discussed its ongoing Phase 3 trials for the ATEV program in dialysis access, planning to submit a supplemental BLA in the second half of 2026, as well as its preclinical progress on a small diameter ATEV for coronary artery bypass grafting. Financially, Humacyte reported a net loss of $148.7 million for 2024, with research and development expenses increasing to $88.6 million, reflecting their expanded clinical activities and manufacturing efforts. The company completed a public offering, raising approximately $46.6 million, which bolsters its cash position for continued development and commercialization efforts.FDA Approval of Symvess
Symvess received full FDA approval for the treatment of extremity vascular trauma, marking an important milestone in vascular surgery. The product went through over 20 years of research and development.
Successful Commercial Launch of Symvess
The commercial launch of Symvess is proceeding well, with 34 hospitals initiating their VAC approval process. The first commercial shipments have already been made to several Level 1 trauma centers.
New Patent Issued
A new U.S. patent covering key aspects of the manufacturing system for Symvess and other bioengineered human tissues has been issued, providing protection into 2040.
Progress in ATEV Program
The V007 Phase 3 clinical trial for ATEV in dialysis access met its co-primary endpoints, showing superior function and patency at 6 and 12 months compared to AV fistula.
Financial Position
Completion of an underwritten public offering of common stock provided approximately $46.6 million in additional net proceeds.
---
HUMA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
HUMA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 28, 2025 | $2.01 | $1.96 | -2.49% |
| Nov 08, 2024 | $5.26 | $5.78 | +9.89% |
| Aug 13, 2024 | $6.62 | $6.65 | +0.45% |
| May 10, 2024 | $4.52 | $4.70 | +3.98% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Humacyte (HUMA) report earnings?
Humacyte (HUMA) is schdueled to report earning on May 09, 2025, TBA Not Confirmed.
What is Humacyte (HUMA) earnings time?
Humacyte (HUMA) earnings time is at May 09, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is HUMA EPS forecast?
HUMA EPS forecast for the fiscal quarter 2025 (Q1) is -0.2.
---